Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
published in: Leukemia
date of publication: 2010-04
language: English
main subject: patient, leukemia, acute myeloid leukemia
Cites articles 23
- 2005-06-01
Date
Title
Article - wd:Q28271726